Clinical trials
Cervical Cancer Screening clinical trials
Below are recruiting cervical cancer screening clinical trials, each written for real people, not researchers. We’re tracking 165 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06527456Recruiting
Boosting cervical cancer screening with help from your doctor
This study tests whether extra support from your regular general practitioner can help more women get screened for cervical cancer. If you qualify, your GP will work with you to make sure you don't miss your screening appointment.
CréteilAges 25–65 - NCT06496295Enrolling by invitation
Testing a new speculum for cervical cancer screening
This trial tests a new kind of vaginal speculum (the tool used to look inside the vagina during a pelvic exam). It is for people who have never had this exam before, to see if it works well for cervical cancer screening.
Englewood, ColoradoAges 18–65 - NCT05606133Recruiting
Test HPV DNA from blood to track cervical cancer risk
This study looks at a blood test that measures HPV DNA to help screen and monitor people with HPV-related cervical problems. If you have confirmed high-grade cervical changes or cervical cancer, the test may help doctors follow how your condition changes over time.
New York, New YorkAges 18 years+ - NCT06254846Recruiting
Urine test for HPV cervical cancer screening
This study tests if a urine sample can replace a cervical swab for HPV testing during cervical cancer screening. If it works, it could make screening easier and less uncomfortable.
Saint-EtienneAges 30–65 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06079671RecruitingPhase 3
Volrustomig for high-risk locally advanced cervical cancer
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
Birmingham, AlabamaAges 15 years+ - NCT06042543Recruiting
Cervical cancer screening trial for unscreened women
This trial tests a new, affordable way to screen for cervical cancer that can be done in low- and middle-income countries. It uses artificial intelligence to help decide who needs follow-up care.
Cincinnati, OhioAges 25–49 - NCT05686226RecruitingPhase 2
Trial tests immune cells targeting HPV-16 cancers
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Bethesda, MarylandAges 18 years+ - NCT05572944Recruiting
Using family risk to predict lung cancer in never-smokers
This study builds and tests risk prediction tools for lung cancer in people who have never smoked, using information from family history. If it works, it may help doctors identify who might need closer screening earlier.
Taichung, TaiwanAges 20–80 - NCT05524480Enrolling by invitation
Help Latina women get overdue breast, cervical care
This trial tests an implementation program that helps clinics better provide breast and cervical cancer screening and HPV vaccination to Latina women who are behind on recommended care. It may help you catch up on screening or start HPV vaccination and connect you to low-cost services.
Houston, TexasAges 18–74 - NCT05544084Recruiting
Patient navigation program for cervical screening in Senegal
This study tests a patient “navigator” approach to improve cervical cancer screening and prevention access in Senegal. You may be invited to help through community education, health facility work, or by being part of a screening-support household.
DakarAges 25–69 - NCT05528237Enrolling by invitation
HPV self-test to help cervical cancer screening access
This trial studies whether letting people collect their own HPV test sample (a private, at-home option) makes cervical cancer screening easier for people with HIV and/or those who are often underserved. If you’ve declined a Pap test or it’s been 6+ months since your last screening, this may offer a more convenient way to check for HPV and cervical cancer risk.
Seattle, WashingtonAges 25 years+ - NCT05475171RecruitingPhase 2
Combination treatment for advanced cervical cancer
This study tests a new combination of immunotherapy drugs for cervical cancer that has spread or returned. It aims to see if the treatment can shrink tumors and improve outcomes for people whose cancer is not curable with standard treatments.
Houston, TexasAges 18 years+ - NCT05483491RecruitingPhase 1
TCR cell therapy for select metastatic cancers
This Phase 1 trial tests a personalized immune-cell treatment (TCR-T cells) for certain metastatic cancers. It targets cancers that carry a specific marker and requires patients to have a specific immune-system match, aiming to improve cancer control when standard options were already tried.
New Brunswick, New JerseyAges 18 years+ - NCT05413798Recruiting
Urine HPV test for cervical cancer screening in HIV
This study looks at whether testing for HPV (the virus that can lead to cervical cancer) using a urine sample can help with cervical cancer screening. It’s for women living with HIV, who may be at higher risk and need effective, easy screening.
Westdene, JohannesburgAges 25 years+ - NCT05390567Recruiting
Mobile reminders to help women catch up on cancer screening
This study tests a mobile outreach effort to help women who are behind on recommended cervical cancer screening. It may help you learn when to get screened and connect you to care that may be easier to access.
Gainesville, FloridaAges 25–65 - NCT05372484Recruiting
Test technology to improve cervical cancer screening and diagnosis
This study tests a new technology to help find cervical cancer earlier by focusing on people who already had an abnormal screening result. It may help improve how abnormal tests are checked and diagnosed.
Houston, TexasAges 25–49 - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05286034Recruiting
AI chatbot to help women join cervical screening
This trial tests whether an AI chatbot can encourage women to take part in cervical cancer screening. It targets women who have not had a recent Pap test and who did not respond to an invitation letter, aiming to improve participation.
CarcassoneAges 30–65 - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT04916990Recruiting
Care program for rural adults with several lung and head cancers
This study looks at how to improve care for adults with certain cancers who live in rural areas and may face access problems. It mainly focuses on people receiving cancer treatment at specific Colorado-area hospitals, and who are uninsured or underinsured.
Aurora, ColoradoAges 18–99 - NCT04865887RecruitingPhase 2
Pembrolizumab plus lenvatinib for advanced cervical cancer
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04226313Recruiting
Home self-swab tests for people not doing cervical screening
This study looks at whether a home self-sampling swab can help people who haven’t joined cervical cancer screening in the past few years. If you qualify, you’ll be asked to collect a swab yourself so it can be tested, aiming to make screening easier to access.
OlomoucAges 30–65 - NCT04107181Recruiting
Speculum-free screening for cervical cancer testing
This pilot study tests a new way to check for cervical cancer that does not use a speculum (a tool used during pelvic exams). If you qualify, you may be offered this alternative screening method as part of the study.
Durham, North CarolinaAges 21–65
Hear when a new Cervical Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cervical cancer screening?
- Yes. Clin2 currently lists 165 recruiting cervical cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cervical cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cervical cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.